Enzymotec (Enzymotec) Change In Payables And Accrued Expense : $2.50 Mil (TTM As of Sep. 2017)

View and export this data going back to 2013. Start your Free Trial

What is Enzymotec Change In Payables And Accrued Expense?

Enzymotec's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2017 was $3.64 Mil. It means Enzymotec's Accounts Payable & Accrued Expense increased by $3.64 Mil from Jun. 2017 to Sep. 2017 .

Enzymotec's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2016 was $-1.89 Mil. It means Enzymotec's Accounts Payable & Accrued Expense declined by $1.89 Mil from Dec. 2015 to Dec. 2016 .

Enzymotec Change In Payables And Accrued Expense Historical Data

The historical data trend for Enzymotec's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymotec Change In Payables And Accrued Expense Chart

Enzymotec Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

3.59

3.05

-3.87

2.30

-1.89

Enzymotec Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.42	-2.94	0.25	1.56	3.64

Enzymotec Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.50 Mil.

Enzymotec Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Enzymotec's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzymotec (Enzymotec) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzymotec Ltd (NAS:ENZY) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.enzymotec.com

Enzymotec Ltd is nutritional and food ingredients company. It develops and manufactures nutritional ingredients and medical foods based on proprietary technologies. Its product portfolio includes Infat, K-Real, Enzy PS solutions, Vayacog, Vayarin and Vayaroll. The company has Nutrition and Vaya Pharma reportable segments. It derives majority of its revenues from Nutrition segment. The firm mainly operates in America, Europe, Australia, Asia, and Israel.

Enzymotec (Enzymotec) Headlines

From GuruFocus

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson • 12-07-2015

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi • 12-20-2016

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon • 07-01-2016